A Multicenter, Double-Blinded, Placebo-Controlled Phase III Clinical Trial to Evaluate the Long-term Efficacy of Recombinant Zoster Vaccine (CHO Cell) in Adults Aged 40 Years and Above
Latest Information Update: 25 Dec 2025
At a glance
- Drugs Herpes zoster vaccine MAXVAX Biotechnology (Primary)
- Indications Herpes zoster
- Focus Adverse reactions; Registrational
- Sponsors MAXVAX Biotechnology
Most Recent Events
- 25 Dec 2025 New trial record